On December 9, at Taipei time, S&P Dow Jones Indices, the world's leading index provider, revealed the results of 2023 Dow Jones Sustainability Indices (DJSI). For the first time, Oneness Biotech Co., Ltd. (TWO.4743) has been selected as an index component of the Dow Jones Sustainability Emerging Markets Index (DJSI) in the Pharmaceuticals sector. This marks a historic achievement, establishing Oneness as the first pharmaceutical company from Taiwan to receive such recognition. The inclusion underscores Oneness' emergence as a prominent global sustainable enterprise.
The DJSI, renowned as the pioneering series of global sustainability benchmarks available in the market, stands out as one of the most credible evaluations in the world. The DJSI are float-adjusted market capitalization weighted indices based on the Corporate Sustainability Assessment (CSA), that measure the performance of companies selected using environmental, social and governance (ESG) criteria. It is also the first time that a pharmaceutical company in Taiwan has been selected into the DJSI, which is a groundbreaking acknowledgment of our ESG performance on the international stage, signifying excellence in a fiercely competitive business landscape.
According to the report, out of the 28 sub-items assessed, 16 ranked in the top 5%, with full scores in product stewardship, transparency and reporting, marketing practices, and occupational health and safety. Innovation management, product quality and recall management, environmental policy and management systems, materiality, business ethics, policy influence, and biodiversity ranked in the top 3% among the global pharmaceutical industry.
Huang Shan-Nei, Chairman of Oneness Biotech, emphasized that ESG is not only a corporate social responsibility but also a sustainable competitive advantage propelling the company's growth. With concerted efforts from all employees, Oneness has introduced various ISO management systems and sustainability-related standards. Over the years, the company has garnered recognition from domestic and international evaluation, achieving a top 5% rating in the Corporate Governance Evaluation by TWSE for two consecutive years and inclusion in the Bloomberg Gender Equality Index for two years. It is a great honor to be selected into the DJSI Emerging Markets Index this year. This is an important milestone for Oneness to promote sustainable development and is the greatest encouragement or all colleagues.
Look beyond, Oneness remains steadfast in its dedication to developing new drugs grounded in its core value: science, integrity, and transparency. We will continue to implement corporate governance in response to global development trends. We aim to achieve the founding purpose of “Developing New Drugs and Caring for Life” by providing effective therapies to the patients with our science and innovation. At the same time, we are advocating for energy-saving policies and implementing low-carbon manufacturing practices for environmental sustainability, while also taking into account the interests of all stakeholders, to create shared value in the context of sustainability.
